Lantern Pharma LTRN Stock
Lantern Pharma Price Chart
Lantern Pharma LTRN Financial and Trading Overview
| Lantern Pharma stock price | 5.83 USD |
| Previous Close | 5.81 USD |
| Open | 5.75 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 5.75 - 6 USD |
| 52 Week Range | 4.05 - 6.59 USD |
| Volume | 37.16K USD |
| Avg. Volume | 28.3K USD |
| Market Cap | 64.16M USD |
| Beta (5Y Monthly) | 0.635033 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.33 USD |
LTRN Valuation Measures
| Enterprise Value | 11.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.736111 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.220318 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.806 |
Trading Information
Lantern Pharma Stock Price History
| Beta (5Y Monthly) | 0.635033 |
| 52-Week Change | 21.47% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.59 USD |
| 52 Week Low | 4.05 USD |
| 50-Day Moving Average | 5.11 USD |
| 200-Day Moving Average | 5.11 USD |
LTRN Share Statistics
| Avg. Volume (3 month) | 28.3K USD |
| Avg. Daily Volume (10-Days) | 45.04K USD |
| Shares Outstanding | 10.86M |
| Float | 7.43M |
| Short Ratio | 4.32 |
| % Held by Insiders | 23.34% |
| % Held by Institutions | 27.28% |
| Shares Short | 139.87K |
| Short % of Float | 1.50% |
| Short % of Shares Outstanding | 1.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.78% |
| Return on Equity (ttm) | -23.76% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -14641114 USD |
| Net Income Avi to Common (ttm) | -14005937 USD |
| Diluted EPS (ttm) | -1.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 51.54M USD |
| Total Cash Per Share (mrq) | 4.75 USD |
| Total Debt (mrq) | 260.22K USD |
| Total Debt/Equity (mrq) | 0.5 USD |
| Current Ratio (mrq) | 19.751 |
| Book Value Per Share (mrq) | 4.843 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13196918 USD |
| Levered Free Cash Flow (ttm) | -9216456 USD |
Profile of Lantern Pharma
| Country | United States |
| State | TX |
| City | Dallas |
| Address | 1920 McKinney Avenue |
| ZIP | 75201 |
| Phone | 972 277 1136 |
| Website | https://www.lanternpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Q&A For Lantern Pharma Stock
What is a current LTRN stock price?
Lantern Pharma LTRN stock price today per share is 5.83 USD.
How to purchase Lantern Pharma stock?
You can buy LTRN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lantern Pharma?
The stock symbol or ticker of Lantern Pharma is LTRN.
Which industry does the Lantern Pharma company belong to?
The Lantern Pharma industry is Biotechnology.
How many shares does Lantern Pharma have in circulation?
The max supply of Lantern Pharma shares is 11.77M.
What is Lantern Pharma Price to Earnings Ratio (PE Ratio)?
Lantern Pharma PE Ratio is now.
What was Lantern Pharma earnings per share over the trailing 12 months (TTM)?
Lantern Pharma EPS is -1.47 USD over the trailing 12 months.
Which sector does the Lantern Pharma company belong to?
The Lantern Pharma sector is Healthcare.
Lantern Pharma LTRN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}